CJC-1295 Ipamorelin Community Reports
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/cjc-1295-no-dac* · *peptides/ipamorelin* · *peptides/sermorelin* · *peptides/tesamorelin*
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Standard dose: 100–200 mcg CJC-1295 no DAC + 200–300 mcg Ipamorelin, injected simultaneously (same syringe — no incompatibility issues reported)
Timing:
- Pre-sleep: primary and most protected window
- Fasted morning: secondary pulse
- Post-workout: optional third pulse
The empty stomach rule: Inject at minimum 2–3 hours after eating. Insulin from a recent meal blunts the GH pulse significantly.
Cycle: 8–12 weeks on → 4–8 weeks off. IGF-1 testing before, during (weeks 4–6), and after is considered best practice.
The “Sandra protocol” reference: A practitioner-designed protocol that circulated in community: 250 mcg each, simultaneous pre-sleep injection, 5 days on/2 off, 8–12 week cycle with labs. Frequently used as the community starting point.
What should I avoid combining — and what's synergistic?
CJC-1295 Ipamorelin Community Reports doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for CJC-1295 Ipamorelin Community Reports yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/cjc-1295-no-dac* · *peptides/ipamorelin* · *peptides/sermorelin* · *peptides/tesamorelin*
The combination's standing in the community
CJC-1295 without DAC + Ipamorelin is the de facto gold standard entry-level GH peptide protocol. When community members ask “where do I start with GH optimization?” this is the standard recommendation. It has effectively become the default because it works reliably, has a clean safety profile, and is well-documented with community self-experiment data including IGF-1 labs.
What the community reports — timeline
Week 1: Sleep is the signal
Deep sleep quality dramatically improved in the first week is the universal first report. Vivid, coherent, memorable dreams are the community’s “it’s working” marker. If vivid dreams don’t appear by week 2, users investigate product quality.
Morning energy follows sleep improvement. Training recovery begins improving before body composition shifts are visible. Users consistently report being able to train harder and more frequently within weeks 2–3.
Weeks 4–8: Body composition becomes visible
Subcutaneous fat reduction (particularly abdominal) is typically first noticed around weeks 4–6. Lean mass improvements are gradual and described as “quality” — more prominent at 8–12 weeks. Skin quality improvements reported at 8+ weeks.
The community’s numerical anchor: An 8-week self-experiment (250 mcg CJC + 250 mcg Ipa, pre-sleep, 5 days/week) documented IGF-1 rising from 168 → 287 ng/mL with no adverse lab changes. This is the most frequently cited data point in community threads about expected outcomes.
Protocol
Standard dose: 100–200 mcg CJC-1295 no DAC + 200–300 mcg Ipamorelin, injected simultaneously (same syringe — no incompatibility issues reported)
Timing:
- Pre-sleep: primary and most protected window
- Fasted morning: secondary pulse
- Post-workout: optional third pulse
The empty stomach rule: Inject at minimum 2–3 hours after eating. Insulin from a recent meal blunts the GH pulse significantly.
Cycle: 8–12 weeks on → 4–8 weeks off. IGF-1 testing before, during (weeks 4–6), and after is considered best practice.
The “Sandra protocol” reference: A practitioner-designed protocol that circulated in community: 250 mcg each, simultaneous pre-sleep injection, 5 days on/2 off, 8–12 week cycle with labs. Frequently used as the community starting point.
Side effects
Mild profile across the board.
- Water retention — most common early side effect; resolves weeks 2–3
- Tingling/paresthesia in extremities — moderate incidence; GH action; usually resolves
- Headache — occasional; dose-dependent
- Joint aches (carpal tunnel-like) — at higher doses or in older users; reverses with dose reduction
- No cortisol, prolactin, or hunger effects (the combination is specifically chosen to avoid these)
Regulatory note (FDA 2024)
In September 2024, the FDA classified CJC-1295 and ipamorelin as compounds that cannot be used in 503A/503B compounding, effectively removing them from the legal US compounding market. Community discussion of this was significant; sourcing shifted. RFK Jr. mentioned potential restoration; current status as of mid-2025 uncertain.
Common community questions
Can I inject both in the same syringe? Yes — widely done with no reported incompatibility.
When do body composition changes start? Don’t expect them before week 4–6. Sleep and recovery come first (week 1–2). Many community members quit too early.
What IGF-1 level am I targeting? Community generally targets upper-normal-range IGF-1 (not supraphysiological). The 8-week self-experiment ending at 287 ng/mL is a commonly cited reference point.
Cross-references
*peptides/cjc-1295-no-dac*— individual CJC-1295 no DAC community data*peptides/ipamorelin*— individual ipamorelin community data*peptides/sermorelin*— alternative GHRH; weaker but accessible*peptides/tesamorelin*— GHRH specialist for visceral fat; stronger for abdominal fat
Commercial note
CJC-1295 Without DAC and Ipamorelin are both available through Alyve — use code OHM-15 at checkout for 15% off.